17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of
17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or
refractory solid tumors or leukemia. Drugs used in chemotherapy, such as
17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop cancer cells from
dividing so they stop growing or die.